BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 12868549)

  • 1. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
    J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Pistella E; Falcone M; Baiocchi P; Pompeo ME; Pierciaccante A; Penni A; Venditti M
    Infez Med; 2005 Jun; 13(2):97-102. PubMed ID: 16220029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
    J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus.
    Maggiolo F; Capra R; Bottura P; Pravettoni G; Migliorino M; Suter F
    J Chemother; 2000 Jun; 12(3):195-8. PubMed ID: 10877512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
    Abb J
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):319-21. PubMed ID: 12151194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antistaphylococcal activity of teicoplanin in Riyadh, Saudi Arabia.
    Shibl AM; Ishag AH; Durgham SM
    APMIS Suppl; 1988; 3():68-70. PubMed ID: 2972301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
    Al-Nawas B; Shah PM
    J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
    Nashev D; Toshkova K; Gavrilova V
    Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.
    Trakulsomboon S; Danchaivijitr S; Rongrungruang Y; Dhiraputra C; Susaemgrat W; Ito T; Hiramatsu K
    J Clin Microbiol; 2001 Feb; 39(2):591-5. PubMed ID: 11158112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates.
    Tabe Y; Nakamura A; Igari J
    J Infect Chemother; 2001 Sep; 7(3):142-7. PubMed ID: 11810575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.
    Maple PA; Hamilton-Miller JM; Brumfitt W
    Antimicrob Agents Chemother; 1991 Feb; 35(2):345-50. PubMed ID: 1827242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.
    Bernard L; Vaudaux P; Rohner P; Huggler E; Armanet M; Pittet D; Lew DP; Schrenzel J
    J Microbiol Methods; 2004 May; 57(2):231-9. PubMed ID: 15063063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
    Blondeau JM; Borsos S; Hesje CK
    J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.
    Tiwari HK; Sen MR
    BMC Infect Dis; 2006 Oct; 6():156. PubMed ID: 17067393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.